Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 1.00 |
| ▸ | ITGAV | P06756 | 14/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13170290 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL14356368 | 0.93 | ITGB3 (0.89) | ITGB3ITGAVITGA2B | |
| SCHEMBL14387907 | 0.93 | ITGB3 (0.86) | ITGB3ITGAVITGA2B | |
| SCHEMBL2419825 | 0.92 | ITGB3 (0.85) | ITGB3ITGAVITGA2B | |
| SCHEMBL23718779 | 0.92 | ITGB3 (0.85) | ITGB3ITGAVITGA2B | |
| SCHEMBL14387730 | 0.92 | ITGB3 (0.85) | ITGB3ITGAVITGA2B | |
| SCHEMBL14387909 | 0.91 | ITGB3 (0.84) | ITGB3ITGAVITGA2B | |
| SCHEMBL14387729 | 0.91 | ITGB3 (0.84) | ITGB3ITGAVITGA2B | |
| SCHEMBL14356372 | 0.91 | ITGB3 (0.85) | ITGB3ITGAVITGA2B | |
| SCHEMBL14356377 | 0.90 | ITGB3 (0.84) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9833520-B2 | Labeled, non-peptidic, multivalent integrin antagonist compounds; methods for synthesis and uses thereof | THE METHODIST HOSPITAL RESEARCH INSTITUTE (US) | 2017-12-05 | — | — | US | disclosed |
| US-20140044646-A1 | Labeled, Non-Peptidic, Multivalent Integrin Antagonist Compounds; Methods for Synthesis and Uses Thereof | THE METHODIST HOSPITAL RESEARCH INSTITUTE (US) | 2014-02-13 | — | — | US | disclosed |
| US-7300940-B2 | Integrin α-v β-3 antagonists for use in imaging and therapy | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300940-B2 | Integrin α-v β-3 antagonists for use in imaging and therapy | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140044646-A1 | Labeled, Non-Peptidic, Multivalent Integrin Antagonist Compounds; Methods for Synthesis and Uses Thereof | ITGB3, ITGAV, ITGB1 | ITGB3 1/4885ITGAV 2/4885ITGA2B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.